AbbVie: Dominating Immunology While Building Oncology Upside
Seeking Alpha
February 17, 2026
The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV stock is a Buy.
Verticals
financemarkets
Originally published on Seeking Alpha on 2/17/2026